Patients with lung cancer stage I–II (mean, 1549.671 ng/ml; median, 1651.749 ng/ml) did not have an elevated anti-IGFBP-2 antibodies compared to patients with lung cancer stage III–IV (1667.397 ng/ml; median, 1648.400 ng/ml) (P= 0.548, Fig. 1B). This evidence concerns the gene IGFBP2 and lung carcinoma.